FGF2 stimulates the proliferation of human mesenchymal stem cells through the transient activation of JNK signaling  by Ahn, Hee-Jin et al.
FEBS Letters 583 (2009) 2922–2926journal homepage: www.FEBSLetters .orgFGF2 stimulates the proliferation of human mesenchymal stem cells through
the transient activation of JNK signaling
Hee-Jin Ahn, Woo-Jung Lee, KyuBum Kwack, Young Do Kwon *
Department of Biomedical Science, Graduate School, CHA University, Gyeonggi-do 487-010, Republic of Korea
a r t i c l e i n f o a b s t r a c tArticle history:
Received 22 April 2009
Revised 27 July 2009
Accepted 30 July 2009
Available online 5 August 2009
Edited by Angel Nebreda
Keywords:
Mesenchymal stem cell
FGF2
c-Jun N-terminal kinase
Proliferation
Differentiation potential0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.07.056
Abbreviations: JNK, c-Jun N-terminal kinase; ERK,
protein kinase; MAPK, mitogen-activated protein kina
* Corresponding author. Fax: +82 31 780 6295
E-mail addresses: ydkwon@cha.ac.kr, ydkwon21@dFGF2 has been shown to enhance proliferation and maintain differentiation potential in hMSCs dur-
ing in vitro propagation. In this study, we investigated the role of mitogen-activated protein kinase
in the functions of FGF2 in hMSCs. We demonstrated that FGF2 induces the transient activation of c-
Jun N-terminal kinase (JNK), but not extracellular signal-regulated protein kinase or p38 protein
kinase. SP600125 and a dominant negative JNK1 signiﬁcantly reduced the FGF2-enhanced prolifer-
ation of hMSCs. Treatment with SP600125 also diminished the activity of FGF2 in the maintenance of
adipogenic and osteogenic differentiation potential. These results suggest that JNK signaling is
involved in the FGF2-induced stimulation of the proliferation and the maintenance of differentia-
tion potential in hMSCs.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human mesenchymal stem cells (hMSCs) can be efﬁciently iso-
lated from adult bone marrow, and are capable of extended prolif-
eration in culture. They have the potential to differentiate into
mesenchymal lineages including osteoblasts, chondrocytes, and
adipocytes [1,2]. It has also been suggested that they can modulate
the host immune responses when transplanted [3,4]. These charac-
teristics make them a promising source of cell-based therapies for
mesenchymal tissues.
Some cytokines are known to enhance the proliferation of
hMSCs. Platelet-derived growth factor (PDGF) induces the prolifer-
ation of hMSCs through the activation of c-Jun N-terminal kinase
(JNK) signaling [5]. Transforming growth factor b1 (TGFb1) also in-
duces the rapid nuclear translocation of b-catenin in a Smad3-
dependent manner and stimulates the proliferation of hMSCs [6].
Previous studies have shown that ﬁbroblast growth factor 2
(FGF2) enhances the growth of hMSCs and maintains their multi-
lineage differentiation potential during in vitro expansion [7–10].
However, the molecular mechanisms involved in the regulationchemical Societies. Published by E
extracellular signal-regulated
se
reamwiz.com (Y.D. Kwon).of the proliferation and differentiation potential of hMSCs are still
unknown.
Fibroblast growth factors constitute a large family of polypep-
tide growth factors involved in a variety of biological processes,
including development, differentiation, cell proliferation, and
angiogenesis [11]. FGFs perform their biological functions by
binding to and activating FGF receptors, a subfamily of cell sur-
face receptor tyrosine kinases [12]. The docking protein FGF
receptor substrate 2 (FRS2), a critical component in FGF signaling,
is activated by FGF receptors, and then recruits the growth factor
receptor-bound protein 2 (GRB2) signal transduction molecule
[13]. This leads to the activation of the Ras-Raf-mitogen-activated
protein kinase (MAPK) signaling pathway via the formation of
FRS2–GRB2–SOS complexes, and on the other side directs the
activation of the PI3K-Akt cell survival pathway by the recruit-
ment of the GRB2-associated binding protein 1 (GAB1) docking
protein. MAPK signaling cascades, mediated by extracellular sig-
nal-regulated protein kinase (ERK), JNK, and p38 protein kinase,
are the major signal transducers for growth factors, cytokines,
and stress, and modulate both cell proliferation and apoptosis
[14].
In this study, we examined the role of MAPKs in the FGF2-in-
duced proliferation and retention of multilineage differentiation
potential of hMSCs. We demonstrate that the transient activation
of JNK, but not ERK or p38 protein kinase, plays a pivotal role in
the FGF2-induced responses in hMSCs.lsevier B.V. All rights reserved.
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2.1. Cell culture and FGF2 treatment
Human bone marrow-derived MSCs were obtained from Camb-
rex Bio Science (Warlkersville, MD). The cells were maintained in
a-MEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bo-
vine serum (Hyclone, Logan, UT) and 20 lg/ml gentamicin (Invitro-
gen). For cell proliferation assay, FGF2 (Invitrogen) was added at a
concentration of 5 ng/ml into growth medium, and for Western
blot analysis the cells were incubated in serum-free medium over-
night and were then treated with 40 ng/ml of FGF2 for indicated
times.
2.2. Cell proliferation assay
Cell proliferation was determined by XTT assay (Roche Diagnos-
tics, Germany). Brieﬂy, hMSCs were seeded at a density of
5000 cells/cm2 and were treated with SP600125, SB202190,
PD98059 (Sigma, St. Louis, MO) and SU5402 (Calbiochem, San Die-
go, CA), or were transduced with lentiviruses at a multiplicity of
infection of 1 for 2 h in the presence of 4 lg/ml of polybrene (Sig-
ma). The cells were treated with 5 ng/ml of FGF2. After 3 days, the
cells were incubated with XTT labeling mixture and then absor-
bance was measured by an ELISA reader (Molecular Devices, Sun-
nyvale, CA) at 490 nm with a reference wavelength at 650 nm.
2.3. Western blot analysis
The cells were washed with Dulbecco’s phosphate-buffered sal-
ine (D-PBS) and were lysed in cell lysis buffer (Promega, Madison,
WI). The total cell lysates were separated by using Nupage 4–12%
Bis-Tris gel (Invitrogen) and were then transferred to polyvinyl
diﬂuoride (PVDF) membranes (Millipore, Bedford, MA). The mem-
branes were blocked with 5% skim milk and were washed with
PBST buffer (Phosphate-buffered saline/0.2% Tween 20). The mem-
branes were blotted with primary antibodies; anti-phospho-ERK,
anti-phospho-p38 (Cell Signaling Technology, Beverly, MA), anti-
phospho-JNK (R&D systems Inc., Minneapolis), anti-JNK, anti-ERK,
anti-p38 and anti-a-tubulin (Santa Cruz Biotechnology Inc., CA).
The blots were treated with appropriate secondary antibodies con-
jugated with horseradish peroxidase (Santa Cruz Biotechnology
Inc.) and were then visualized by enhanced chemiluminescence
system (ECL, Amersham Biosciences, UK).
2.4. JNK activity assay
JNK activity was measured by a SAPK/JNK assay kit (Cell Signal-
ing Technology) according to the manufacturer’s instructions.
Brieﬂy, the cell extracts were incubated with GST-c-Jun fusion pro-
teins bound to glutathione agarose beads and were precipitated by
centrifugation. The pellets were suspended in kinase buffer and
incubated for 30 min at 30 C. The phospho-c-Jun proteins were
detected by Western blot analysis using phospho-c-Jun antibody
and ECL system. As a loading control, c-Jun was detected by using
c-Jun antibody (Santa Cruz Biotechnology Inc.).
2.5. Construction of a dominant negative JNK1 and lentivirus
production
The dominant negative JNK1 (dnJNK1) mutant was created by
replacing Thr183 and Tyr185 with Ala and Phe, respectively, by
PCR-based mutagenesis method (Stratagene, La Jolla, CA) according
to manufacturer’s directions. The dnJNK1 was subcloned into the
pWPT-GFP lentiviral vector (kindly provided from Dr Didier Trono,Switzerland; http://tronolab.epﬂ.ch) at BamHI and MluI sites. The
GFP and dnJNK1-GFP lentiviruses were produced in 293FT cell line
(Invitrogen) by transient transfection with lentiviral vectors and
three packaging plasmids, pLP1, pLP2, and pLP/VSVG (Invitrogen).
The functional virus titers were determined by ﬂow cytometry
using FACS Calibur (Becton Dickinson) in NIH3T3 cell line.
2.6. hMSC differentiation
For induction of hMSC differentiation, the cells were seeded at a
density of 20 000 cells/cm2. After 2 days, the conﬂuent hMSCs were
treated with adipogenic medium (10% FBS, 10 lg/ml insulin,
0.5 mM isobutyl-methylxanthine, 20 lM indomethacin and 1 lM
dexamethasone in DMEM) and with osteogenic medium (10% FBS,
100 nM dexamethasone, 50 lM ascorbic acid, 10 mM glycerol-2-
phosphate in a-MEM). After 2 weeks, the accumulation of intracel-
lular triglyceride droplets was visualized by Oil Red O staining.
After 1 week of differentiation, ALP staining (Sigma, St. Louis) was
performed according to the manual provided with the kit.
2.7. Quantitative real-time RT-PCR
Total RNA was isolated from hMSCs after 1 week of differentia-
tion induction by using Trizol reagent (Invitrogen). First-strand
cDNA was synthesized by the SuperScript system (Invitrogen). PCR
ampliﬁcation conditions were 20 s denaturation at 94 C, 30 s
annealing at 55 C, and 30 s extension at 72 C for all genes. PCR
primers were as follows: GAPDH, 50-GAGTCAACGGATTTGGTCGT-30
and 50-TTGATTTTGGAGGGATCTCG-30; OC, 50-AGAGTCCAGCAAA
GGTGCAG-30 and 50-TCAGCCAACTCGTCACAGTC-30; RUNX2, 50-CC
TCCTACCTGAGCCAGATG-30 and 50-ACTGAGAGTGGAAGGCCA
GA-30; BSP, 50-CAACAGCACAGAGGCAGAAA-30 and 50-CGTACTCCC
CCTCGTATTCA-30; PPARg2, 50-TCCATGCTGTTATGGGTGAA-30 and
50-TCAAAGGAGTGGGAGTGGTC-30; LPL, 50-GGGCATGTTGACATT
TACCC-30 and 50-AGCCCTTTCTCAAAGGCTTC-30; aP2, 50-CATCAG
TGTGAATGGGGATG-30 and 50-TGCACATGTACCAGGACACC-30. PCR
reactionwas performed by QuantiTech SYBR Green PCR kit (Qiagen,
Germany) and Exicycler 96 system (Bioneer, Korea).
3. Results
3.1. FGF2 stimulates the proliferation of hMSCs
The effect of FGF2 on the proliferation of hMSCs was deter-
mined from cell growth kinetics. FGF2-treated cells showed
approximately 60% more population doublings than untreated
cells for 5 weeks before growth arrest, and consequently 64-fold
more cells were generated (Fig 1A). This result suggests that
FGF2 increases the proliferation rate of hMSCs.
During the in vitro expansion of hMSCs, the cell morphology
changed gradually from a ﬁbroblast-like spindle shape to a ﬂat-
tened and enlarged shape, which is one of the properties of senes-
cent cells [15]. FGF2 treatment delayed the change in cell
morphology (Fig. 1B). This result suggests that FGF2 stimulates
the proliferation of hMSCs through the suppression of senescence.
3.2. JNK signaling is involved in the FGF2-induced proliferation of
hMSCs
In order to examine the role of MAPKs in the FGF2-stimulated
proliferation of hMSCs, we assessed the effects of MAP kinase
inhibitors. Treatment with SP600125, a JNK inhibitor, completely
blocked FGF2-induced proliferation (Fig. 2A) and the inhibition of
JNK activity by SP600125 was veriﬁed by JNK activity assay
(Supplementary Fig. S1). In contrast, SB202190, a p38 inhibitor,
Fig. 1. Effects of FGF2 on the growth and morphology of hMSCs. (A) Cells were cultured in the presence or absence of 5 ng/ml of FGF2. The cells were replated every week and
the cell numbers were counted. Cumulative population doublings (PDs) were plotted against time in culture. (B) Light microscopy photographs of the control cells and FGF2-
treated cells. The cells were cultured for 3 weeks in the presence or absence of FGF2 supplementation (magniﬁcation; 100).
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ERK, exerted only minimal effects on the growth stimulatory activ-
ity of FGF2 (Fig. 2A). FGF2-speciﬁc cell proliferation was conﬁrmed
by growth inhibition by the treatment of SU5402, a FGF receptor
inhibitor (Fig. 2A). This result suggests the involvement of JNK sig-
naling in FGF2-induced proliferation of hMSCs although SB202190
does not affect all p38 isoforms.
To investigate the effects of FGF2 on the activation of MAPKs,
we conducted Western blot analysis of phosphorylated MAPKs.
As shown in Fig. 2B, FGF2 induced the rapid phosphorylation of
JNK, and the phosphorylated form of p46 JNK was detected more
strongly than that of p54 JNK. However, the levels of phospho-
p38 and phospho-ERK were not increased by FGF2 treatment. Con-
sistent with the effects of MAPK inhibitors on FGF2-stimulated
proliferation, these results indicate that FGF2 induces the activa-
tion of JNK but does not signiﬁcantly affect other MAPKs.
Because the speciﬁcity of SP600125 is limited [16], a dominant
negative JNK1 (dnJNK1) was used to evaluate the effects of the spe-
ciﬁc inhibition of JNK signaling. For highly efﬁcient gene delivery,
control GFP and dnJNK1-GFP were subcloned into a lentiviral vec-
tor. As shown in Fig. 2C, the exogenous expression of dnJNK1-GFP
and the endogenous expression of JNK in hMSCs was veriﬁed by
Western blot analysis with JNK antibody. The inhibition of JNK
activity by dnJNK1-GFP was conﬁrmed by reduction in phosphory-
lation of c-Jun in JNK activity assay. The dnJNK1-GFP lentivirus
infection signiﬁcantly reduced the FGF2-stimulated proliferation
of hMSCs. This result further conﬁrms that FGF2 induces the prolif-
eration of hMSCs via the activation of JNK.
3.3. FGF2 Induces the transient activation of JNK signaling
To further characterize the activation of JNK by FGF2, JNK activ-
ity was assayed by the phosphorylation of GST-c-Jun fusion protein
as a substrate. After hMSCs were treated with FGF2, we observed
immediate JNK activation within 5 min (Fig. 3A), but this JNK activ-
ity declined rapidly within 2 h. To assess more precisely the dura-
tion of the JNK activation induced by FGF2, we performed a pulse
experiment in which hMSCs were stimulated with FGF2 for
20 min and then the FGF2 was removed. After the pulse of FGF2,
JNK activity increased, but decreased rapidly again within 20 min
(Fig. 3B). These results indicate that FGF2 induces the rapid and
transient activation of JNK. They are consistent with previous re-
ports demonstrating that the transient activation of JNK can signal
cell survival or proliferation, whereas sustained JNK activation can
mediate proapoptotic signaling [17,18].
3.4. JNK signaling is involved in the FGF2-mediated maintenance of
differentiation potential
FGF2 signiﬁcantly prevents the reduction of the differentiation
potential of hMSCs during in vitro expansion [8]. In order to deter-mine whether FGF2 maintains the differentiation potential
through the activation of JNK, the hMSCs were cultured with
FGF2 in the presence or absence of SP600125 for 2 weeks under
the normal culture condition, and were then differentiated into
preadipocytes or osteoblasts. As shown in Fig. 4A, culture in the
presence of SP600125 reduced the formation of lipid droplets in-
duced by FGF2 treatment. RT-PCR analysis showed that FGF2 treat-
ment increased the expression of adipogenesis-related genes, such
as PPARc2 (peroxisome proliferator-activated receptor gamma 2),
LPL (lipoprotein ligase), and aP2 (adipocyte fatty acid binding pro-
tein 2), whereas the addition of SP600125 inhibited the FGF2-en-
hanced gene expression. In the case of osteogenic differentiation,
treatment with SP600125 diminished the effect of FGF2 which in-
creased ALP (alkaline phosphatase) activity and the expression of
osteogenesis-related genes, such as RUNX2 (runt-related transcrip-
tion factor 2), OC (osteocalcin), and BSP (bone sialoprotein),
(Fig. 4B). These results suggest that the FGF2-mediated mainte-
nance of hMSC differentiation potential requires the activation of
JNK signaling.4. Discussion
The application of hMSCs to cell-based therapies requires the
in vitro expansion and retention of their multilineage differentia-
tion potential. FGF2 is known to augment the mitotic and differ-
entiation potentials of hMSCs [7–10]. In this study, we
demonstrated that FGF2 induces the transient activation of JNK
and that JNK signaling is involved in the FGF2-induced stimula-
tion of proliferation and the maintenance of differentiation poten-
tial in hMSCs.
We showed that FGF2 induces the phosphorylation of JNK, but
not ERK or p38, in hMSCs. This is an unfamiliar observation in
that MAPKs are usually regulated coordinately, i.e. mitogenic sig-
nals activate ERKs and JNKs, and stress signals simultaneously in-
duce the activation of JNKs and p38 [19,20]. However, it has been
reported that a lethal dose of UV-C induces JNK activation, but
does not affect p38 or ERK activity in Jurkat cells [17]. Moreover,
the functionality of the ERK and p38 pathways in our hMSCs was
conﬁrmed by treatment of PDGF, as a positive control [5]. There-
fore, it was thought that the activation of only JNK by FGF2 in
hMSCs was the result of experimental conditions or the cellular
context.
Previous reports have suggested that the duration of JNK activa-
tion is the determining factor in certain distinct biological re-
sponses [17,18]. In other words, transient JNK activation induces
cell proliferation or survival, whereas apoptotic signaling requires
sustained JNK activation. Consistent with these previous studies,
FGF2 induced the transient activation of JNK and enhanced the
proliferation of hMSCs. In contrast, the prolongation of JNK activa-
tion by co-treatment with FGF2 and sodium orthovanadate, a
FGF2
P-JNK
JNK
P-ERK
ERK
P-p38
P38
-tubulin
0      5    15   30   60   120     (min)
— dnJNK1-GFP
— p54 JNK
— p46 JNK
1   2
P-c-Jun
c-Jun
A
B
C
0
* * SP PD SB SU
C
el
l p
ro
llf
er
at
lo
n 
(%
)
C
el
l p
ro
llf
er
at
lo
n 
(%
)
50
100
150
200
250
300
control
FGF2
Mock
0
50
100
150
200
250
GFP dnJNK1-GFP
Fig. 2. FGF2 induces the activation of JNK signaling in hMSCs. (A) Cells were
pretreated with DMSO (vehicle), 10 lM SP600125 (SP), 10 lM PD98059 (PD),
10 lM SB202190 (SB), or 20 lM SU5402 (SU) for 20 min, and then FGF2 was added
at a concentration of 5 ng/ml. After 3 days, cell proliferation was measured with an
XTT assay. Data are expressed as a percentage of the vehicle-treated control. (B) The
cells were incubated in serum-free medium overnight and were then treated with
40 ng/ml of FGF2. After the indicated times, cell lysates were prepared and the
phosphorylation of MAPKs was examined by Western blot analysis. JNK, ERK, p38
and a-tubulin were used to conﬁrm equal loading. Representative data from three
or more independent experiments are shown. (C) Cells were infected with GFP or
dominant negative JNK1-GFP (dnJNK1-GFP) lentiviruses at a multiplicity of
infection of 1, and the exogenous expression of dnJNK1-GFP (70 kDa) was
conﬁrmed by Western blot analysis with JNK antibody. FGF2 was added to hMSCs
infected with GFP or dnJNK1-GFP lentiviruses and then the inhibition of JNK activity
by dnJNK1-GFP was examined by JNK activity assay (lane 1; GFP, lane 2; dnJNK1-
GFP). After lentivirus infection, hMSCs were cultured with 5 ng/ml of FGF2 for 3
days. Cell proliferation was measured with an XTT assay and the data are expressed
as a percentage of the mock-infected control.
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Fig. 3. FGF2 induces the rapid and transient activation of JNK. (A) Serum-starved
hMSCs were treated with 40 ng/ml of FGF2, and at the indicated times, cell lysates
were prepared and JNK activity was assayed by the phosphorylation of GST-c-Jun
fusion protein as a substrate. c-Jun was used as a loading control. (B) Serum-starved
cells were stimulated with FGF2 for 20 min and then the FGF2 was removed. At the
indicated times after the pulse of FGF2, the phosphorylation of c-Jun was assessed
(pre; before FGF2 treatment, FGF2; treatment with FGF2 for 20 min). c-Jun was used
as a loading control.
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shown). These ﬁndings suggest that dual speciﬁcity (threonine/
tyrosine) phosphatase activity is critically important in regulating
the time course of JNK activation, and that transient JNK activation
may induce the genes required for cell proliferation and the pre-
vention of apoptosis.Recently, it was reported that FGF2 promotes cell proliferation
and HGF secretion through JNK signaling pathway in adipose-de-
rived stem/stromal cells (ASCs) which have similar characters in
the expression pattern of cell surface markers and multilineage dif-
ferentiation potential with bone marrow-derived hMSCs [21]. In a
mouse model of ischemia-reperfusion injury of adipose tissue, the
authors showed that FGF2 is released by injured adipose tissue,
and FGF2-induced proliferation and HGF secretion of ASCs contrib-
utes to the regeneration of adipose tissue. A similar mechanism of
the biological role of FGF2 and ASCs in adipose tissue regeneration
may be also implicated in bone marrow-derived hMSCs because
the cells are known to secrete many cytokines for tissue regenera-
tion [22].
Self-renewal of stem cells implies two properties: proliferation
and the retention of differentiation potential. These two features
are known to be regulated in a coordinated fashion by common
pathways including Oct4, NANOG, and SOX2 in embryonic stem
cells [23]. During in vitro expansion, the growth rate of hMSCs
slows in concert with the reduction in their differentiation capac-
ity, and FGF2 can signiﬁcantly prevent this gradual loss of self-re-
newal of hMSCs. In our study, a dominant negative JNK1
suppressed the FGF2-stimulated proliferation of hMSCs, and treat-
ment with SP600125 reduced the activity of FGF2 in the mainte-
nance of adipogenic and osteogenic differentiation potentials.
Our results show that the suppression of JNK signaling concur-
rently prevents the FGF2-induced proliferation and maintenance
of differentiation potential in hMSCs, suggesting the existence of
a common pathway regulating the proliferation and the differenti-
ation capacity of hMSCs.
It has been previously demonstrated that SP600125 promotes
adipogenesis by increasing the expression of adipogenic transcrip-
tion factors and represses osteogenesis from hMSCs under the dif-
ferentiation medium [24]. However, pretreatment with SP600125
during normal culture before differentiation induction did not in-
crease adipogenic differentiation (Supplementary Fig. S2). In our
experiment, hMSCs were treated with FGF2 and SP600125 for 2
weeks under normal culture condition and were then induced to
differentiate without FGF2 and SP600125 (Fig. 4). Therefore, adipo-
genic differentiation was not increased by SP600125 pretreatment
and we could obtain the results that the co-treatment of SP600125
with FGF2 diminishes the FGF2-enhanced expression of adipogen-
esis-related genes.
Fig. 4. Maintenance of the differentiation potential of hMSCs mediated by FGF2 requires the activation of JNK signaling. Cells were cultured with 5 ng/ml of FGF2 in the
presence or absence of 10 lM of SP600125 for 2 weeks under normal culture condition, and were then differentiated into preadipocytes or osteoblasts without FGF2 and
SP600125. (A) Lipid droplet accumulation was visualized with Oil Red O staining (magniﬁcation; 40). RT-PCR analysis was performed for adipogenesis-related genes
(PPARc2, LPL, and aP2). (B) Alkaline phosphatase activity was examined by ALP staining (magniﬁcation; 40). RT-PCR analysis was performed for osteogenesis-related genes
(RUNX2, OC, and BSP).
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